What is Biogen's TOFIDENCE — total revenue?

Biogen (BIIB) reported TOFIDENCE — total revenue of $0 in Q1 2026.

How has Biogen's TOFIDENCE — total revenue changed year-over-year?

Biogen's TOFIDENCE — total revenue decreased by 100.0% year-over-year, from $100K to $0.

What does TOFIDENCE — total revenue mean?

This metric represents the total gross sales generated from the commercialization of the Tofidence product line. It reflects the market adoption and revenue contribution of this specific therapeutic asset within the company's broader immunology or biosimilar portfolio. Monitoring this figure helps investors assess the product's lifecycle stage, competitive positioning, and its impact on overall top-line growth.

Biogen BIIB TOFIDENCE — Total Revenue

Other product segments

TYSABRI

$441.5M+15.7%

SPINRAZA

$374M-11.8%

VUMERITY

$179M+29.0%

AVONEX

$163.2M-2.2%

SKYCLARYS

$150.7M+21.6%

BENEPALI

$122.1M+9.7%

TECFIDERA

$109.5M-46.9%

PLEGRIDY

$64.3M+8.1%

ZURZUVAE

$55.4M+100%

IMRALDI

$49.6M+4.6%

QALSODY

$32.5M+110%

FLIXABI

$10.5M-19.8%

BYOOVIZ

$0-100%

FAMPYRA

$0-100%

FUMADERM And ADUHELM

$0-100%

Similar metrics at other companies

CRMDDefenCath — Total Revenue

$97.51M+150%

GILDOdefsey — Total revenues

$221M-21.4%

RVTYTotal Revenue

$711.12M+7.0%

JAZZTotal Revenue

$1.07B+19.1%

TVTXTiopronin products — Total Revenue

$19.34M-3.2%

BMYCobenfy — Total Revenues

$56M+107%

Other financials

Income statement

See full

Revenue$2.5B+1.9%

Gross profit$1.8B+0.8%

Operating income$610.7M—

Net income$319.5M+32.8%

EPS (diluted)$2.15+31.1%

Balance sheet

See full

Cash & equivalents$3.4B+30.2%

Total debt$6.6B+34.7%

Total equity$18.7B+9.9%

Total assets$29.5B+5.2%

Cash flow

See full

Operating cash flow$645.5M+149%

CapEx$51.2M+38.0%

Free cash flow$594.3M+167%

Valuation

See full

Market cap$31.89B+72.3%

Enterprise value$35.07B+57.0%

P/E22.5×+10.4×

P/S3.2×+1.4×

Profitability

See full

Gross margin75.5%-0.1pp

Operating margin22.9%—

Net margin14.3%-0.8pp

FCF margin24.4%-0.4pp

Returns & leverage

See full

Return on equity8%-1.2pp

Debt / equity0.4×+0.1×

Current ratio3.1×+1.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biogen's tofidence — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Biogen's TOFIDENCE — total revenue?: Biogen (BIIB) reported TOFIDENCE — total revenue of $0 in Q1 2026.
How has Biogen's TOFIDENCE — total revenue changed year-over-year?: Biogen's TOFIDENCE — total revenue decreased by 100.0% year-over-year, from $100K to $0.
What does TOFIDENCE — total revenue mean?: This metric represents the total gross sales generated from the commercialization of the Tofidence product line. It reflects the market adoption and revenue contribution of this specific therapeutic asset within the company's broader immunology or biosimilar portfolio. Monitoring this figure helps investors assess the product's lifecycle stage, competitive positioning, and its impact on overall top-line growth.